Epidemiological trends in asthma

Canadian Respiratory Journal

Volumn 3, Issue 4, 1996, Pages 261-268

  Sears, Malcolm R ^a  

^a ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Asthma; Epidemiology

Indexed keywords

ALLERGEN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FENOTEROL;

ADOLESCENT; ADULT; AIR POLLUTION; ASTHMA; ATOPY; CANADA; CHILD; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; WHEEZING;

EID: 0029792016     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/1996/410215     Document Type: Review

References (74)

1. Cullinan P. Respiratory disease in England and Wales. Thorax 1988;43:949-54.
2. Vollmer WM, Osborne ML, Buist AS. Temporal trends in hospital-based episodes of asthma care in a health maintenance organization. Am Rev Respir Dis 1993;147:347-53.
3. Kun HY, Oates RK, Mellis CM. Hospital admissions and attendances for asthma - a true increase? Med J Aust 1993;159:312-3.
4. Gergen PJ, Weiss KB. Changing patterns of asthma hospitalization among children: 1979 to 1987. JAMA 1990;264:1688-92.
5. Gerstman BB, Bosco LA, Tomita DK. Trends in the prevalence of asthma hospitalization in the 5 to 14 year old Michigan Medicaid population, 1980 to 1986. J Allergy Clin Immunol 1993;91:838-43.
6. Costello J. Asthma - the problem and the paradox. Postgrad Med J 1991;67:S1-5.
7. Sinclair BL, Clark DWJ, Sears MR. Use of anti-asthma drugs in New Zealand. Thorax 1987;42:670-5.
8. Klaukka T, Peura S, Martikainen J. Why has the utilization of antiasthmatics increased in Finland? J Clin Epidemiol 1991;44:859-63.
9. Bauman A. Has the prevalence of asthma symptoms increased in Australian children? J Paediatr Child Health 1993;29:424-8.
10. Sears MR. Epidemiology. In: Barnes PJ, Rodger IW, Thomson NC, eds. Asthma: Basic Mechanisms and Clinical Management, 2nd edn. San Diego: Academic Press 1992:1-19.
11. Whallett EJ, Ayres JG. Labelling shift from acute bronchitis may be contributing to the recent rise in asthma mortality in the 5-34 age group. Respir Med 1993;87:183-6.
12. Ninan TK, Russell G. Respiratory symptoms and atopy in Aberdeen schoolchildren: evidence from two surveys 25 years apart. BMJ 1992;304:873-5.
13. Omram M, Russell G. Continuing rise in the prevalence of asthma-like symptoms and diagnosed atopic disease in Aberdeen schoolchildren. Eur Respir J 1995;8(Suppl 19):495s.
14. Burr ML, Butland BK, King S, Vaughan-Williams E. Changes in asthma prevalence: two surveys 15 years apart. Arch Dis Child 1989;64:1452-6.
15. Burney PGJ, Bousquet J. Evidence for an increase in atopic disease and possible causes. Clin Exp Allergy 1993;23:484-92.
16. Taylor B, Wadsworth J, Wadsworth M, Peckham C. Changes in the reported prevalence of childhood eczema since the 1939-45 war. Lancet 1984;ii:1255-7.
17. Nakagomi T, Itaya H, Tominaga T, Yamaki M, Hisamatsu S, Nakagoma O. Is atopy increasing? Lancet 1994;343:121-2.
18. Frischer T, Kuehr J, Meinert R, et al. Maternal smoking in early childhood: a risk factor for bronchial responsiveness to exercise in primary school children. J Pediatr 1992;121:17-22.
19. Taylor B, Wadsworth J. Maternal smoking during pregnancy and lower respiratory tract illness in early life. Arch Dis Child 1987;62:786-91.
20. Weiss ST. Environmental tobacco smoke and asthma. Chest 1993;104:991-2.
21. Cunningham J, Dockery DW, Speizer FE. Maternal smoking during pregnancy as a predictor of lung function in children. Am J Epidemiol 1994;139:1139-52.
22. Oryszczyn MP, Godin J, Annesi I, Hellier G, Kauffmann F. In utero exposure to parental smoking, cotinine measurements, and cord blood IgE. J Allergy Clin Immunol 1991;87:1169-74.
23. Sherrill DL, Martinez FD, Lebowitz MD, et al. Longitudinal effects of passive smoking on pulmonary function in New Zealand children. Am Rev Respir Dis 1992;145:1136-41.
24. Schmitzberger R, Rhomberg K, Buchele H, et al. Effects of air pollution on the respiratory tract of children. Pediatr Pulmonol 1993;15:68-74.
25. Walters S, Griffiths RK, Ayres JG. Temporal association between hospital admissions for asthma in Birmingham and ambient levels of sulphur dioxide and smoke. Thorax 1994;49:133-40.
26. Von Mutius E, Martinez FD, Fritzsch C, Nicolai T, Roell G, Thiemann HH. Prevalence of asthma and atopy in two areas of West and East Germany. Am J Respir Crit Care Med 1994;149:358-64.
27. Manfreda J, Yeung M, Dimich-Ward H, et al. Prevalence of asthma-like symptoms in four Canadian cities. Am J Respir Crit Care Med 1995;151:A29.
28. Sears MR, Herbison GP, Holdaway MD, Hewitt CJ, Flannery EM, Silva PA. The relative risks of sensitivity to grass pollen, house dust mite and cat dander in the development of childhood asthma. Clin Exp Allergy 1989;19:419-24.
29. Peat JK, Tovey E, Gray EJ, Mellis CM, Woolcock AJ. Asthma severity and morbidity in a population sample of Sydney schoolchildren: Part II - importance of house dust mite allergens. Aust NZ J Med 1994;24:270-6.
30. Sears MR, Holdaway MD, Flannery EM, Herbison GP, Silva PA. Parental and neonatal risk factors for atopy, airway hyperresponsiveness and asthma in children. Arch Dis Child. (In press)
31. von Mutius F, Martinez FD, Fritzsch C, Nicolai T, Reitmeir P, Thiemann HH. Skin test reactivity and number of siblings. BMJ 1994;308:692-5.
32. Seidman DS, Laor A, Gale R, Stevenson DK, Danon YL. Is low birth weight a risk factor for asthma during adolescence? Arch Dis Child 1991;66:584-7.
33. Arshad SH, Hide DW. Effect of environmental factors on the development of allergic disorders in infancy. J Allergy Clin Immunol 1992;90:235-41.
34. Kuehr J, Frischer T, Karmaus W, Meinert R, Barth R, Urbanek R. Clinical atopy and associated factors in primary-school pupils. Allergy 1992;47:650-5.
35. Chan KN, Elliman A, Bryan E, Silverman M. Clinical significance of airway responsiveness in children of low birthweight. Pediatr Pulmonol 1989;7:251-8.
36. Backer V, Ulrik SU, Hansen KK, Laursen EM, Dirksen A, Bach-Mortensen N. Atopy and bronchial responsiveness in a random population sample of 527 children and adolescents. Ann Allergy 1992;69:116-22.
37. Rea H, Sears M, Mitchell E, Garrett J, Mulder J, Anderson R. Is asthma becoming more severe? Thorax 1987;42:736.
38. De Andrade AD, Birnbaum J, Lanteaume A, et al. Housing and house-dust mites. Allergy 1995;50:142-6.
39. Custovic A, Taggart SCO, Woodcock A. House dust mite and cat allergen in different indoor environments. Clin Exp Allergy 1994;24:1164-8.
40. 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology. Drug Saf 1994;11:259-83.
41. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990;336:1391-6.
42. Taylor DR, Sears MR, Herbison GP, et al. Regular inhaled beta-agonist in asthma: effect on exacerbations and lung function. Thorax 1993;48:134-8.
43. Cockcroft DW, McPaarland CP, Britto SA, Swystun VA, Rutherford BC. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993;342:833-7.
44. Cockcroft DW, O'Byrne PM, Swystun VA, Bhagat R. Regular use of inhaled albuterol and the allergen-induced late asthmatic response. J Allergy Clin Immunol 1995;96:44-9.
45. Gauvreau GM, Watson RM, Jordana M, Cockcroft D, O'Byrne PM. The effect of regular inhaled salbutamol on allergen-induced airway responses and inflammatory cells in blood and induced sputum. Am J Respir Crit Care Med 1995;151:A39.
46. Inman MD, O'Byrne PM. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am J Respir Crit Care Med 1996;153:65-9.
47. Chapman KR, Kesten S, Szalai JP. Regular vs as-needed inhaled salbutamol in asthma control. Lancet 1994;343:1379-82.
48. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild to moderate asthma. N Engl J Med 1992;327:1420-5.
49. Richter B, Buselic K, Heisters J, Richter A, Berger M. Continuous versus on demand inhaled β-agonist therapy on the basis of regular inhaled corticosteroids: a randomised controlled study. Eur Respir J 1995;8(Suppl 19): 159s.
50. 2-agonist dose reduction in asthma. Aust NZ J Med 1994;24:460.
51. Sears MR. Dose reduction of beta-agonists in asthma. Lancet 1991;338:1331-2.
52. Inman WHW, Adelstein AM. Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols. Lancet 1969;ii:279-85.
53. Jackson RT, Beaglehole R, Rea HH, Sutherland DC. Mortality from asthma: a new epidemic in New Zealand. BMJ 1982;285:771-4.
54. Vital Statistics of the United States. Hyattsville: US Department of Health, Education and Welfare, National Center for Health Statistics, Public Health Service, Annual Reports 1977-87.
55. Mortality Statistics, England and Wales. London: Office of Population, Censuses and Surveys, Health Statistics, Annual Reports 1976-91.
56. Sears MR, Rea HH, Beaglehole R, et al. Asthma mortality in New Zealand: a two year national study. NZ Med J 1985;98:271-5.
57. Sears MR, Rea HH, De Boer G, et al. Accuracy, of certification of deaths due to asthma. A national study. Am J Epidemiol 1986;124:1004-11.
58. Rea HH, Sears MR, Beaglehole R, et al. Lessons from the national asthma mortality study: circumstances surrounding death. NZ Med J 1987;100:10-3.
59. British Thoracic Association. Death from asthma in two regions of England. BMJ 1982;285:1251-5.
60. Johnson AJ, Nunn AJ, Somner AR, Stableforth DE, Stewart CJ. Circumstances of death from asthma. BMJ 1984;288:1870-2.
61. Barger LW, Vollmer WM, Felt RW, Buist AS. Further investigation into the recent increase in asthma death rates: a review of 41 asthma deaths in Oregon in 1982. Ann Allergy 1988;60:31-9.
62. Miller BD, Strunk RC. Circumstances surrounding the deaths of children due to asthma. A case-control study. Am J Dis Child 1989;143:1294-9.
63. Sur S, Crotty TB, Kephart GM, et al. Sudden onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am Rev Respir Dis 1993;148:713-9.
64. Ulrik CS, Frederiksen J. Mortality and markers of risk of asthma death among 1,075 outpatients with asthma. Chest 1995;108:10-5.
65. Spitzer WO, Suissa S, Ernst P, et al. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 1992;326:501-6.
66. Ernst P, Habbick B, Suissa S, et al. Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity? Am Rev Respir Dis 1993;148:75-9.
67. Suissa S, Blais L, Ernst P. Patterns of increasing β-agonist use and the risk of fatal or near-fatal asthma. Eur Respir J 1994;7:1602-9.
68. Committee on Safety of Medicines. Beta agonist use in asthma: report from the CSM Working Party [Report no 33]. London: CSM, 1992.
69. Taylor DR, Sears MR. Regular beta-adrenergic agonists. Evidence, not reassurance, is what is needed. Chest 1994;106:552-9.
70. McFadden ER, Gilbert IA. Asthma. N Engl J Med 1992;327:1928-37.
71. 2-agonists and their antagonists. Chest 1994;106:329-31.
72. Wanner A. Is the routine use of inhaled β-adrenergic agonists appropriate in asthma treatment? Yes. Am J Respir Crit Care Med 1995;151:597-9.
73. Pearce N, Beasley R, Crane J, Burgess C, Jackson R. End of the New Zealand asthma mortality epidemic. Lancet 1995;345:41-4.
74. Ernst P, FitzGerald JM, Spier S. Canadian Asthma Consensus Conference: summary of recommendations. Can Respir J 19663:89-100.